There are currently 417 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Spectrum Health - Butterworth Campus, Trinity Health Grand Rapids Hospital and CCOP - Grand Rapids. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Chemotherapy
NCT04829539
Recruiting
This phase III trial compares BBT-CI to HEAL for the reduction of insomnia in patients with stage I-IV cancer who are receiving cancer treatment. Cancer treatment can cause side effects such as sleep problems. Sleep problems such as insomnia, are common for cancer patients. Insomnia can be described as difficulty falling asleep, waking up many times during the night or waking up earlier than patient would like. Insomnia can increase fatigue and worsen quality of life. This trial may help researc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2024
Locations: Spectrum Health at Butterworth Campus, Grand Rapids, Michigan
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
NCT04509050
Recruiting
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).
Gender:
ALL
Ages:
10 years and below
Trial Updated:
08/08/2024
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Cystic Fibrosis
Register for Updates
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
NCT06529029
Recruiting
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/30/2024
Locations: Pine Rest Christian Mental Health Services, Grand Rapids, Michigan
Conditions: Suicidal Ideation, Major Depressive Disorder, Schizo Affective Disorder, Bipolar Disorder
Register for Updates
Assessment of the Utility of the Pantheris Small Vessel (SV) System
NCT04793581
Recruiting
A single-arm study to assess the utility of the Pantheris SV catheter in addressing peripheral artery disease in arteries located below the knee. Data will be collected on the percent stenosis pre- and post-atherectomy and then symptoms and adverse events noted at 30 days, 6 months, and 1 year after the procedure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Advanced Cardiac and Vascular Centers, Grand Rapids, Michigan
Conditions: Peripheral Arterial Disease
Register for Updates
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
NCT03128996
Recruiting
This study is designed to estimate the efficacy and toxicity of familial HLA mismatched bone marrow transplants in patients with non-malignant disease who are less than 21 years of age and could benefit from the procedure.
Gender:
ALL
Ages:
Between 1 day and 21 years
Trial Updated:
07/22/2024
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766
Recruiting
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2024
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan +2 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706
Recruiting
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: South Texas Accelerated Research Therapeutics (START), Grand Rapids, Michigan
Conditions: Metastatic Solid Tumor
Register for Updates
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
NCT03926520
Recruiting
This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/30/2024
Locations: Pine Rest Christian Mental Health Services, Grand Rapids, Michigan
Conditions: Alzheimer Dementia, Agitation,Psychomotor
Register for Updates
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
NCT04092673
Recruiting
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumor, Adult
Register for Updates
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
NCT06086522
Recruiting
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumor
Register for Updates